Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy | Zendy

John M. Lachin | Zendy; Giancarlo Viberti | Zendy; Bernard Zinman | Zendy; Steven M. Haffner | Zendy; R. Paul Aftring | Zendy; Gitanjali Paul | Zendy; Barbara G. Kravitz | Zendy; William H. Herman | Zendy; Rury R. Holman | Zendy; Steven E. Kahn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy

Author(s) -

John M. Lachin,

Giancarlo Viberti,

Bernard Zinman,

Steven M. Haffner,

R. Paul Aftring,

Gitanjali Paul,

Barbara G. Kravitz,

William H. Herman,

Rury R. Holman,

Steven E. Kahn

Publication year - 2011

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.09291010

Subject(s) - rosiglitazone , medicine , metformin , albuminuria , type 2 diabetes , renal function , endocrinology , diabetes mellitus , glycemic , creatinine , urology

In ADOPT (A Diabetes Outcomes Prevention Trial), initial monotherapy with rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine differences in albumin excretion, renal function (estimated GFR), and BP over 5 years between treatment groups.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research